HRP20030432A2 - Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation - Google Patents

Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation Download PDF

Info

Publication number
HRP20030432A2
HRP20030432A2 HR20030432A HRP20030432A HRP20030432A2 HR P20030432 A2 HRP20030432 A2 HR P20030432A2 HR 20030432 A HR20030432 A HR 20030432A HR P20030432 A HRP20030432 A HR P20030432A HR P20030432 A2 HRP20030432 A2 HR P20030432A2
Authority
HR
Croatia
Prior art keywords
ondansetron hydrochloride
ondansetron
hydrochloride form
ethanol
degrees
Prior art date
Application number
HR20030432A
Other languages
English (en)
Croatian (hr)
Inventor
Judith Aronhime
Revital Lifshitz
Valerie Niddam
Ramy Lidor-Hadas
Asher Maymon
Shlomit Weizel
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HRP20030432A2 publication Critical patent/HRP20030432A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
HR20030432A 2000-10-30 2001-10-30 Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation HRP20030432A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24428300P 2000-10-30 2000-10-30
US25381900P 2000-11-29 2000-11-29
US26553901P 2001-01-31 2001-01-31
PCT/US2001/048720 WO2002036558A2 (en) 2000-10-30 2001-10-30 Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation

Publications (1)

Publication Number Publication Date
HRP20030432A2 true HRP20030432A2 (en) 2004-06-30

Family

ID=27399743

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030432A HRP20030432A2 (en) 2000-10-30 2001-10-30 Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation

Country Status (20)

Country Link
US (1) US20020107275A1 (cs)
EP (1) EP1339707A2 (cs)
JP (1) JP2004525083A (cs)
KR (1) KR20030042038A (cs)
CN (1) CN1498216A (cs)
AU (1) AU2002230935A1 (cs)
CA (1) CA2426026A1 (cs)
CZ (1) CZ20031397A3 (cs)
DE (1) DE01991193T1 (cs)
ES (1) ES2204358T1 (cs)
HR (1) HRP20030432A2 (cs)
HU (1) HUP0401239A2 (cs)
IL (1) IL155644A0 (cs)
IS (1) IS6797A (cs)
MX (1) MXPA03003761A (cs)
NO (1) NO20031928L (cs)
PL (1) PL366150A1 (cs)
SK (1) SK6182003A3 (cs)
WO (1) WO2002036558A2 (cs)
YU (1) YU32003A (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156835A0 (en) * 2001-01-11 2004-02-08 Teva Pharma An improved process for preparing pure ondansetron hydrochloride dihydrate
EP1499623B1 (en) 2002-04-29 2007-06-13 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-¬(2-methyl-1h-imidazol-1-yl)methyl|-4h-carbazol-4-one
FI6164U1 (fi) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronmuotoja
EP1828141A4 (en) * 2004-10-26 2009-04-01 Ipca Lab Ltd STAINING METHOD FOR PREPARING THE ANTIEMETIC 1,2,3,9-TETRAHYDRO-9-METHYL-3 - [(2-METHYL) -1H-IMIDAZOLE-1-YL) METHYL] -4H-CARBAZOLE-4-ON
CN103211779B (zh) * 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
ES2533563T5 (es) * 2006-01-27 2018-07-24 Adare Pharmaceuticals, Inc. Sistemas de suministro de fármacos que comprenden fármacos débilmente básicos y ácidos orgánicos
US20100105724A1 (en) * 2006-12-07 2010-04-29 Helsinn Healthcare Sa Crystalline and amorphous forms of palonosetron hydrochloride
US8133506B2 (en) 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
US9701636B2 (en) 2013-11-15 2017-07-11 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
EP0201165B1 (en) * 1985-03-14 1994-07-20 Beecham Group Plc Medicaments for the treatment of emesis
GB8518741D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Process
GB8518742D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Process
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
JPH06508836A (ja) * 1991-06-26 1994-10-06 セプラコア，インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
CA2106642C (en) * 1992-10-14 2005-08-16 Peter Bod Carbazolone derivatives and process for preparing the same
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
CN1045437C (zh) * 1994-12-29 1999-10-06 中国科学院上海有机化学研究所 恩丹西酮及其生理盐的合成
EP1207160A1 (en) * 2000-11-20 2002-05-22 Hanmi Pharm. Co., Ltd. Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)-methyl)-4H-carbazol-4-one
EP1499623B1 (en) * 2002-04-29 2007-06-13 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-¬(2-methyl-1h-imidazol-1-yl)methyl|-4h-carbazol-4-one
HRP20041136A2 (en) * 2002-04-30 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Novel crystal forms of ondansetron, processes fortheir preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them

Also Published As

Publication number Publication date
WO2002036558A2 (en) 2002-05-10
AU2002230935A1 (en) 2002-05-15
US20020107275A1 (en) 2002-08-08
CZ20031397A3 (cs) 2003-11-12
IS6797A (is) 2003-04-29
DE01991193T1 (de) 2004-07-08
CN1498216A (zh) 2004-05-19
WO2002036558A3 (en) 2003-02-06
PL366150A1 (en) 2005-01-24
MXPA03003761A (es) 2003-07-28
YU32003A (sh) 2006-05-25
CA2426026A1 (en) 2002-05-10
NO20031928L (no) 2003-06-27
KR20030042038A (ko) 2003-05-27
IL155644A0 (en) 2003-11-23
ES2204358T1 (es) 2004-05-01
JP2004525083A (ja) 2004-08-19
NO20031928D0 (no) 2003-04-29
HUP0401239A2 (hu) 2004-12-28
SK6182003A3 (en) 2004-03-02
EP1339707A2 (en) 2003-09-03

Similar Documents

Publication Publication Date Title
CA2465597A1 (en) Amorphous and crystalline forms of losartan potassium and process for their preparation
EP3433232A1 (en) Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine
RS56464B1 (sr) Oblik iv ivabradin hidrohlorida
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
HRP20030432A2 (en) Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
CN110291079A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
CN101568531A (zh) Mglur5受体拮抗剂的多晶型物
HRP20040767A2 (en) Desolvating solvates of atorvastatin hemi-calcium
HRP20100281A2 (hr) Kristalni oblici palonosetron hidroklorida
CN115819257A (zh) 维兰特罗三苯乙酸盐的新结晶形式及其制备方法
WO2008137134A2 (en) Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
US7271269B2 (en) Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
US7655800B2 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
ZA200303000B (en) Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation.
CN118632851A (zh) (S)-5-苄基-N-(5-甲基-4-氧代-2,3,4,5-四氢吡啶并[3,2-b][1,4]氧氮杂卓-3-基)-4H-1,2,4-三唑-3-甲酰胺的晶型
HK40079891A (en) Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
CN116239569A (zh) 一种半琥珀酸拉司米地坦晶型及其制备方法
US20080182877A1 (en) Rimonabant forms and methods of making the same
HK40079890A (en) Compositions and methods related to picolinylpiperidine 5-ht1f agonists
AU2023206890A1 (en) Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
SI21509A (sl) Priprava tetrazolskega derivata v novi kristalni obliki

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040922

Year of fee payment: 4

OBST Application withdrawn